A multicenter phase II study of docosahexaenoic acid (DHA) in patients with a history of breast cancer, premalignant lesions, or benign breast disease task order period of performance: 9/29/2014 -…
Ended Awarded Last action
- Contract number
- HHSN26100006
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $716,626
Award facts
- Contract value 100% obligated
- $716,626.48 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost No Fee
- Place of performance
- Houston, TX 77230, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$3,607 | |
| Funding Only Action | -$21,253 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $55,882 | |
| Original award | $685,604 |
About this award
This federal contract award is for a multicenter Phase II clinical study of docosahexaenoic acid (DHA) in patients with a history of breast cancer, premalignant lesions, or benign breast disease. The $716,626.48 award was made to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, by the National Cancer Institute under the Cancer Prevention Agent Development Program. The period of performance is from September 2014 to March 2016, with a final completion date of September 2016. This award is not designated as a set-aside. MD Anderson, a large academic medical center and comprehensive cancer treatment and research facility, has extensive experience conducting clinical trials and cancer research supported by federal contracts and grants.
Description
A multicenter phase II study of docosahexaenoic acid (DHA) in patients with a history of breast cancer, premalignant lesions, or benign breast disease task order period of performance: 9/29/2014 - 3/30/2016
Quick answers
Who was awarded contract HHSN26100006?
HHSN26100006 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 19, 2014.
How much is contract HHSN26100006 worth?
The government has obligated $716,626 on HHSN26100006.
Is contract HHSN26100006 an order under another contract?
Yes. HHSN26100006 is a delivery order under HHSN261201200034I, an indefinite delivery contract, on Cancer Prevention Agent Development Program 2012-2017.
Was contract HHSN26100006 competed?
The extent of competition for HHSN26100006 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award